SG11202005990RA - Process for providing pegylated protein composition - Google Patents

Process for providing pegylated protein composition

Info

Publication number
SG11202005990RA
SG11202005990RA SG11202005990RA SG11202005990RA SG11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA
Authority
SG
Singapore
Prior art keywords
protein composition
pegylated protein
providing
providing pegylated
composition
Prior art date
Application number
SG11202005990RA
Other languages
English (en)
Inventor
Wolfgang Koehnlein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11202005990RA publication Critical patent/SG11202005990RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/20Partition-, reverse-phase or hydrophobic interaction chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202005990RA 2017-12-29 2018-12-28 Process for providing pegylated protein composition SG11202005990RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17211124 2017-12-29
PCT/EP2018/097122 WO2019129876A1 (en) 2017-12-29 2018-12-28 Process for providing pegylated protein composition

Publications (1)

Publication Number Publication Date
SG11202005990RA true SG11202005990RA (en) 2020-07-29

Family

ID=60954809

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005990RA SG11202005990RA (en) 2017-12-29 2018-12-28 Process for providing pegylated protein composition

Country Status (7)

Country Link
US (1) US20200323993A1 (zh)
EP (1) EP3731871B1 (zh)
JP (2) JP7137625B2 (zh)
KR (1) KR102523239B1 (zh)
CN (1) CN111741770A (zh)
SG (1) SG11202005990RA (zh)
WO (1) WO2019129876A1 (zh)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1991006666A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
DK0779362T4 (da) 1989-12-22 2012-07-30 Serono Lab DNA-konstruktioner til aktivering og modifikation af endogene geners ekspression
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
WO1994001451A2 (en) 1992-07-13 1994-01-20 Bionebraska, Inc. Method for modification of recombinant polypeptides
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EA004685B1 (ru) 1999-01-29 2004-06-24 Эмджен Инк. Конъюгаты гксф
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
CA2450950A1 (en) * 2001-06-22 2003-01-03 Pharmacia Corporation Chemically-modified progenipoietin conjugates
WO2004056852A2 (en) 2002-12-19 2004-07-08 Nektar Therapeutics Al, Corp. Cyanovirin variant-polymer conjugates
EA200700380A1 (ru) 2004-08-31 2007-10-26 Фармация Энд Апджон Компани Ллс Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AU2009292643B2 (en) * 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2011064247A1 (en) 2009-11-24 2011-06-03 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
PL2616101T3 (pl) * 2010-09-14 2015-01-30 Hoffmann La Roche Sposób oczyszczania pegylowanej erytropoetyny
EP2825205A1 (en) * 2012-03-16 2015-01-21 Belrose Pharma Inc. Polymeric conjugates of c1-inhibitors

Also Published As

Publication number Publication date
KR20200104380A (ko) 2020-09-03
EP3731871C0 (en) 2023-10-04
EP3731871A1 (en) 2020-11-04
JP2021508715A (ja) 2021-03-11
WO2019129876A1 (en) 2019-07-04
US20200323993A1 (en) 2020-10-15
JP7137625B2 (ja) 2022-09-14
EP3731871B1 (en) 2023-10-04
JP2022169794A (ja) 2022-11-09
CN111741770A (zh) 2020-10-02
KR102523239B1 (ko) 2023-04-18

Similar Documents

Publication Publication Date Title
HK1249527A1 (zh) Cd137特異性的蛋白
DK3445788T3 (en) Novel bispecific polypeptides against cd137
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
GB201503133D0 (en) Chimeric protein
IL288613A (en) Multispecific proteins
SG11201704010UA (en) Fibroin-derived protein composition
ZA201708041B (en) Novel proteins specific for lag-3
DK3737402T3 (en) Modificeret protein
GB201608197D0 (en) Novel proteins
GB201511787D0 (en) Proteins
IL258570A (en) Stable protein preparations
EP3463414C0 (en) PROTEIN INTERFACES
GB201515745D0 (en) Proteins
EP3377633C0 (en) PRODUCTION OF RECOMBINANT PROTEINS
HK1257745A1 (zh) 肽組合物
GB201513033D0 (en) Proteins
SG11202006140TA (en) Process for providing pegylated protein composition
GB2558968B (en) G Proteins
ZA202003722B (en) Modified globin proteins
ZA201901862B (en) Modified factor h binding protein
SG11202005990RA (en) Process for providing pegylated protein composition
SG11202005952TA (en) Process for providing pegylated protein composition
EP3505624A4 (en) COMPOSITION FOR ANTI-RNA VIRUS WITH EPRS PROTEIN OR FRAGMENT THEREOF
GB201704006D0 (en) Modified globin proteins